These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 38420130)

  • 1. Injecting drug use and hepatitis C virus infection independently increase biomarkers of inflammatory disease risk which are incompletely restored by curative direct-acting antiviral therapy.
    Hearps AC; Vootukuru N; Ebrahimnezhaddarzi S; Harney BL; Boo I; Nguyen L; Pavlyshyn D; Dietze PM; Drummer HE; Thompson AJ; Jaworowski A; Hellard ME; Sacks-Davis R; Doyle JS
    Front Immunol; 2024; 15():1352440. PubMed ID: 38420130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling hepatitis C micro-elimination among people who inject drugs with direct-acting antivirals in metropolitan Chicago.
    Tatara E; Gutfraind A; Collier NT; Echevarria D; Cotler SJ; Major ME; Ozik J; Dahari H; Boodram B
    PLoS One; 2022; 17(3):e0264983. PubMed ID: 35271634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale-up of direct-acting anti-viral therapy in community drug services: real-world data.
    Palmateer NE; McAuley A; Dillon JF; McDonald S; Yeung A; Smith S; Barclay S; Hayes P; Shepherd SJ; Gunson RN; Goldberg DJ; Hickman M; Hutchinson SJ
    Addiction; 2021 Oct; 116(10):2893-2907. PubMed ID: 33651446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. All-cause mortality before and after DAA availability among people living with HIV and HCV: An international comparison between 2010 and 2019.
    Requena MB; Protopopescu C; Stewart AC; van Santen DK; Klein MB; Jarrin I; Berenguer J; Wittkop L; Salmon D; Rauch A; Prins M; van der Valk M; Sacks-Davis R; Hellard ME; Carrieri P; Lacombe K;
    Int J Drug Policy; 2024 Feb; 124():104311. PubMed ID: 38184902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating the Consensus hepatitis C Cascade of Care among people who inject drugs in Australia: Pre and post availability of direct acting antiviral therapy.
    Iversen J; Dore GJ; Starr M; Catlett B; Cunningham P; Geddes L; Maher L
    Int J Drug Policy; 2020 Sep; 83():102837. PubMed ID: 32645585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temporal trends in HCV treatment uptake and success among people who inject drugs in Baltimore, MD since the introduction of direct acting antivirals.
    Coyle CR; Gicquelais RE; Genberg BL; Astemborski J; Falade-Nwulia O; Kirk GD; Thomas DL; Mehta SH
    Drug Alcohol Depend; 2023 Dec; 253():. PubMed ID: 38456165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Everybody living with a chronic disease is entitled to be cured": Challenges and opportunities in scaling up access to direct-acting antiviral hepatitis C virus treatment among people who inject drugs.
    Goodyear T; Ti L; Carrieri P; Small W; Knight R
    Int J Drug Policy; 2020 Jul; 81():102766. PubMed ID: 32416525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs.
    Grebely J; Bruneau J; Lazarus JV; Dalgard O; Bruggmann P; Treloar C; Hickman M; Hellard M; Roberts T; Crooks L; Midgard H; Larney S; Degenhardt L; Alho H; Byrne J; Dillon JF; Feld JJ; Foster G; Goldberg D; Lloyd AR; Reimer J; Robaeys G; Torrens M; Wright N; Maremmani I; Norton BL; Litwin AH; Dore GJ;
    Int J Drug Policy; 2017 Sep; 47():51-60. PubMed ID: 28683982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "I want to get better, but…": identifying the perceptions and experiences of people who inject drugs with respect to evolving hepatitis C virus treatments.
    Goodyear T; Brown H; Browne AJ; Hoong P; Ti L; Knight R
    Int J Equity Health; 2021 Mar; 20(1):81. PubMed ID: 33740984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved health-related quality of life after hepatitis C viraemic clearance among people who inject drugs may not be durable.
    McDonald SA; Myring G; Palmateer NE; McAuley A; Beer L; Dillon JF; Hollingworth W; Gunson R; Hickman M; Hutchinson SJ
    Addiction; 2023 Jul; 118(7):1340-1350. PubMed ID: 36808787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study.
    Valerio H; Alavi M; Conway A; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Murray C; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Stevens A; Prain B; Hayllar J; Reid D; Montebello M; Wade A; Christmass M; Cock V; Dore GJ; Grebely J;
    Int J Drug Policy; 2022 Jul; 105():103706. PubMed ID: 35533635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the Efficacies of Direct-Acting Antiviral Treatment for HCV Infection in People Who Inject Drugs and Non-Drug Users.
    Hsu JT; Hsu PI; Shie CB; Chuah SK; Wu IT; Huang WW; Tang SY; Tsai KF; Kuo LF; Ghose S; Hsu JC; Shih CA
    Medicina (Kaunas); 2022 Mar; 58(3):. PubMed ID: 35334612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) - a natural experiment (protocol).
    Hickman M; Dillon JF; Elliott L; De Angelis D; Vickerman P; Foster G; Donnan P; Eriksen A; Flowers P; Goldberg D; Hollingworth W; Ijaz S; Liddell D; Mandal S; Martin N; Beer LJZ; Drysdale K; Fraser H; Glass R; Graham L; Gunson RN; Hamilton E; Harris H; Harris M; Harris R; Heinsbroek E; Hope V; Horwood J; Inglis SK; Innes H; Lane A; Meadows J; McAuley A; Metcalfe C; Migchelsen S; Murray A; Myring G; Palmateer NE; Presanis A; Radley A; Ramsay M; Samartsidis P; Simmons R; Sinka K; Vojt G; Ward Z; Whiteley D; Yeung A; Hutchinson SJ
    BMJ Open; 2019 Sep; 9(9):e029538. PubMed ID: 31551376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of primary hepatitis C virus infection among people who inject drugs in Australia pre- and post-unrestricted availability of direct acting antiviral therapies.
    Iversen J; Wand H; McManus H; Dore GJ; Maher L
    Addiction; 2023 May; 118(5):901-911. PubMed ID: 36524842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C treatment uptake among people who inject drugs in Oslo, Norway: A registry-based study.
    Malme KB; Ulstein K; Finbråten AK; Wüsthoff LEC; Kielland KB; Hauge J; Dalgard O; Midgard H
    Int J Drug Policy; 2023 Jun; 116():104044. PubMed ID: 37149914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between depressive symptoms and adherence to direct-acting antivirals: Implications for Hepatitis C treatment among people who inject drugs on medications for opioid use disorder.
    Pericot-Valverde I; Heo M; Niu J; Rennert L; Norton BL; Akiyama MJ; Arnsten J; Litwin AH
    Drug Alcohol Depend; 2022 May; 234():109403. PubMed ID: 35306390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Life after hepatitis C cure in HIV-infected people who inject drugs and men who have sex with men treated with direct-acting antivirals in France: Health perceptions and experiences from qualitative and quantitative findings (ANRS CO13 HEPAVIH).
    Mora M; Goodyear T; Marcellin F; Shoveller J; Di Beo V; Calzolaio C; Sogni P; Wittkop L; Zucman D; Poizot-Martin I; Lacombe K; Salmon-Céron D; Knight R; Carrieri P
    J Viral Hepat; 2020 Dec; 27(12):1462-1472. PubMed ID: 32810905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-Reported Outcomes During and After Hepatitis C Virus Direct-Acting Antiviral Treatment Among People Who Inject Drugs.
    Cheng Q; Cunningham EB; Shih S; Amin J; Bruneau J; Artenie AA; Powis J; Litwin AH; Cooper C; Dalgard O; Hellard M; Bruggmann P; Marks P; Lacombe K; Stedman C; Read P; Hajarizadeh B; Dunlop AJ; Conway B; Feld JJ; Dore GJ; Grebely J;
    Value Health; 2023 Jun; 26(6):883-892. PubMed ID: 36646278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. "Stigma is where the harm comes from": Exploring expectations and lived experiences of hepatitis C virus post-treatment trajectories among people who inject drugs.
    Goodyear T; Brown H; Browne AJ; Hoong P; Ti L; Knight R
    Int J Drug Policy; 2021 Oct; 96():103238. PubMed ID: 33902968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Awareness of hepatitis C virus infection status among people who inject drugs in a setting of universal direct-acting antiviral therapy: The ETHOS Engage study.
    Valerio H; Conway A; Alavi M; Treloar C; Silk D; Murray C; Henderson C; Amin J; Read P; Degenhardt L; Christmass M; Montebello M; Dore GJ; Grebely J;
    Int J Drug Policy; 2022 Dec; 110():103876. PubMed ID: 36240657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.